-
MAPS, Eight Capital And Integrated V.C. Backs Numinus $6M Offering
Friday, February 2, 2024 - 1:58pm | 396Read More...The TDR Three Takeaways: Numinus Wellness Inc. partners with Eight Capital in a $6 million bought deal, involving the purchase of 50,000,000 units, strengthening the company’s financial position for future mental health initiatives. The involvement of MAPS and Integrated V.C. in Numinus...
-
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Saturday, January 6, 2024 - 4:59pm | 659Read More...A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit Corporation has secured over $100 million in a Series A private stock sale. The funds will support the final stages of its application for...
-
MDMA Assisted Therapy Approval And Commercialization Projected Within Calendar 2024 Timeline
Thursday, June 22, 2023 - 12:18pm | 1168Read More...As the Psychedelic Science 2023 Conference in Denver wears on, interesting tidbits of data are emerging into the public sphere. As attendees of the conference—hosted by Multidisciplinary Association for Psychedelic Studies (MAPS)—drip information out on social...
-
Numinus Partners With MAPS To Conduct Phase 1 MDMA Assisted Therapy Investigational Study
Friday, June 16, 2023 - 1:06pm | 630Read More...In a prelude to what is hoped will be regulatory approval of MDMA-assisted therapy in the U.S. and Canada, Numinus Wellness Inc. (OTC: NUMIF) has taken steps to get out in front of the curve. Today, the company has announced a partnership with the Multidisciplinary...
-
Ecstasy Research Trial Completes Enrollment, Moves Closer To Approval To Treat PTSD
Tuesday, May 10, 2022 - 11:51am | 343Read More...The non-profit Multidisciplinary Association for Psychedelics Studies (MAPS) and its subsidiary MAPS Public Benefit Corporation finished the enrollment stage for the second Phase 3 clinical trial on MDMA (MAPP2). A year later after publishing the results from its first Phase 3 trial...
-
EXCLUSIVE: Catalysts To Watch For In The Psychedelic Space
Tuesday, April 19, 2022 - 5:19pm | 405Read More...Any biotech investor knows how important catalysts are for the companies in the space. One FDA approval or denial can make or break the price of the stock. In the psychedelic space, catalysts could be even more important, as the industry as a whole is still in its infancy. At the...
-
DEA Under Fire For Blocking Psilocybin As Treatment For Terminally Ill Cancer Patients
Thursday, April 14, 2022 - 2:38pm | 646Read More...The Drug Enforcement Administration (DEA) will face activists at its headquarters in Arlington, Virginia, reported Mary-Elizabeth Gifford and Justin Grant of Lucid News. Protestors intend to block the entrance to the building to call attention to the rights of terminally ill...
-
These 3 Psychedelic Stocks Will Benefit When The FDA Green-Lights MDMA (Molly, Ecstasy)
Wednesday, April 6, 2022 - 3:57pm | 601Read More...What Happened: According to the Multidisciplinary Association of Psychedelic Studies (MAPS), a non-profit organization, the FDA is close to greenlighting MDMA as a treatment for PTSD. MAPS reported positive results from a phase-3 trial testing the efficacy of MDMA-assisted...
-
Novamind Partners With Bienstar Wellness, Opening Door To Ibogaine Treatment For Addiction Disorders
Thursday, December 2, 2021 - 2:30pm | 480Read More...Novamind Inc. (OTCQB: NVMDF) a mental health company specializing in psychedelic medicine, recently announced a strategic investment and advisory agreement with Bienstar Wellness Corp, an Uruguay-based mental health company, to assist in the expansion of Latin America's first network of...
-
Psychedelic Therapy Execs On Latest Developments In Space, Remaining Hurdles
Friday, May 14, 2021 - 10:53am | 428Read More...Assisted psychedelic treatment executives came together at the two-day, virtual Benzinga Global Small Cap Conference on Thursday to discuss recent lab developments and the significant hurdles ahead in mental health and addiction treatment. Forbes' Will Yakowicz moderated the digital...
-
Your Google Apps Can Now Turn To The Dark Side
Monday, November 23, 2015 - 4:29pm | 414Read More...Ahead of the much anticipated Star Wars film, Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) is getting in on the action. "Wouldn't it be cool if there was some sort of Star Wars thingy in Search?" Google's Clay Bavor, VP of Product Management asked in a blog post. Users of...
-
Apple's 5 Biggest Catastrophes Of The Last 5 Years
Sunday, November 2, 2014 - 1:27pm | 648Read More...Apple Inc. (NASDAQ: AAPL) has had a lot of hits in the form of computers, MP3 players, smartphones and tablets. Not every venture has been successful, however. Some of Apple's issues proved that it is not always wise to Think Different. 5. Supporting The Wrong Sapphire Supplier Apple can't be...
-
Are Apple Execs Begging For A 'Radically New' Product?
Friday, May 16, 2014 - 12:15pm | 479Read More...The Mac maker has not introduced a new product category since the original iPad was released in April 2010. Since that time, Apple (NASDAQ: AAPL) has upgraded its tablet four times (two of which occurred in the same year) and released two ‘mini' variations. Apple also revised the MacBook Air...
-
Sources: Apple Set To Offer iPad Multitasking
Wednesday, May 14, 2014 - 11:58am | 647Read More...According to 9to5 Mac, Apple's (NASDAQ: AAPL) upcoming iOS 8 will offer split-screen multitasking similar to that on Microsoft's Surface tablet series. Sources told the website the feature would allow users to run and interact with two iPad applications at once, including the ability to drag...
-
Surprise Data About the Success of Apple Maps
Tuesday, November 12, 2013 - 9:23am | 494Read More...Remember when Apple (NASDAQ: AAPL) was the butt of every map joke when it released its map app along with iOS 6? The feedback was so negative that CEO Tim Cook apologized and told people to download Google's (NASDAQ: GOOG) version until the problem was corrected. Since then, people have said...
















